Tangle of Tau proteins

Stabilizing protein Tau

BACE1

Complementactivation

Phagocytosis

Phagocytosis

Cytokine productioneg., TNFα secretion

Neurodegeneration

activation

TREM2

CR1CLU

Loss offunction in AD?

Loss offunction in AD?

Transcription

M I C R O G L I A

N E U R O N

Apoptoticcell bodiesHinders repair

Aβ build-up and plaque formationNeurotoxic

APPs

Aβ

A

B

B

Astrocyte

Microglia

ApoE4

Healthy microtubule

Alzheimer’s microtubule

Healthy microtubule

Alzheimer’s microtubuleAmyloidplaque

Tau tangles

A

Potential treatments

β-secretase inhibitors

Notch-sparing γ-secretase inhibitors or modulators

Aβ vaccines and monoclonal antibodies

Aβ aggregation inhibitors

Tau-lowering or anti-aggregation compounds

Regulators of abnormal

Aβ dimers and higher oligomers bind to neuronsand alter membrane protein function

ApoE4 proteindecreases clearanceof extracellular Aβ

Aβ monomers help regulatenormal synaptic transmission

MARK, GSK3,other kinase activities

Tau release extracellularlyand “pathogenic spread”?

APP, PS1, and PS2 mutationsincrease relative Aβ42 production

One APP mutation decreasesAβ production and prevents AD

PS-γAICD

APP processing

Aβ

Aβ

Aβ

X

TREM1TREM1

X

SnapShot: Pathobiology of Alzheimer’s DiseaseDennis J. SelkoeCenter for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA

Cellular Dynamics International, Inc. CDI is a leading developer and manufac-

turer of fully functioning human cells in in-

dustrial quantities to precise specifications.

CDI's proprietary iCell Operating System

(iCell® O/S) includes true human cells in

multiple cell types (iCell products), human

induced pluripotent stem cells (iPSCs) and

custom iPSCs and iCell products (MyCell®

Products). CDI's iCell O/S products pro-

vide standardized, easy-to-use, cost-ef-

fective access to the human cell, the small-

est fully functioning operating unit of

human biology. Customers use our iCell

O/S products, among other purposes, for

drug discovery and screening; to test the

safety and efficacy of their small molecule

and biologic drug candidates; for stem cell

banking; and in the research and develop-

ment of cellular therapeutics. CDI was

founded in 2004 by Dr. James Thomson, a

pioneer in human pluripotent stem cell re-

search at the University of Wiscon-

sin-Madison. CDI's facilities are located in

Madison, Wisconsin, with a second facility

in Novato, California.

See www.cellulardynamics.com